In June of 2023 Fibrogen announced the results of the ZEPHYRUS-1 clinical trial of Pamrevlumab in IPF. Pamrevlumab entered phase 3 with much anticipation. Phase 2 work suggested that the molecule had a high chance of success. Unfortunately, in the phase 3 study which included 356 subjects, Pamrevlumab was not effective at preserving lung function. As a result, Fibrogen … [Read more...]
Staying Healthy During Respiratory Virus Season
Especially Important for Pulmonary Fibrosis Patients Part 1 of 2 In medicine the only intervention better than an effective treatment for a disease is a way to prevent getting the disease in the first place. As Influenza (Flu) season approaches, I am always reminded that in our high tech world of modern medicine with pills that can cost $100,000 per year, one of the most … [Read more...]